Free tool
FAERS Monitor: Tezspire
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761224 or its brand name (Tezspire, Tezepelumab-Ekko). Reports on generic versions are filed under their own applications.
Reports
6,931
Serious
3,128
45% of reports
Hospitalization
1,280
Death reported
255
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthma1,067
- dyspnoea649
- drug ineffective552
- arthralgia551
- product dose omission issue355
- cough342
- pneumonia294
- fatigue273
- headache259
- back pain242
- rash239
- pain233
- injection site pain217
- dizziness204
- device leakage199
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 8 |
| 2021 | 7 |
| 2022 | 588 |
| 2023 | 1,252 |
| 2024 | 1,589 |
| 2025 | 1,785 |
| 2026 | 1,697 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,228 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| asthmaSignal | 1,067 | 28.9 | 27.4 | 28,609 |
| device leakageSignal | 199 | 14.0 | 12.2 | 2,381 |
| arthralgiaSignal | 551 | 4.0 | 3.7 | 1,273 |
| coughSignal | 342 | 3.7 | 3.3 | 681 |
| product dose omission issueSignal | 355 | 3.7 | 3.3 | 695 |
| dyspnoeaSignal | 649 | 3.5 | 3.2 | 1,176 |
| back painSignal | 242 | 3.2 | 2.8 | 359 |
| pneumoniaSignal | 294 | 2.8 | 2.5 | 332 |
| injection site painSignal | 217 | 2.1 | 1.9 | 134 |
| rash | 239 | 1.7 | 1.5 | 64 |
| drug ineffective | 552 | 1.3 | 1.2 | 34 |
| headache | 259 | 1.3 | 1.1 | 13 |
| dizziness | 204 | 1.2 | 1.1 | 10 |
| pain | 233 | 1.2 | 1.0 | 5 |
| fatigue | 273 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.